VIRIDIAN THERAPEUTICS INC (VRDN) Stock News

Notable Two Hundred Day Moving Average Cross - VRDN

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts

Notable Monday Option Activity: VRDN, USB, WOLF

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked.

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival

The results are also promising for the next-generation version of that drug.

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VRDN Stock Earnings: Viridian Therapeutics Misses EPS, Misses Revenue for Q2 2024

VRDN stock results show that Viridian Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)